IAMPOV has provided for the display of scientific posters related to the focus of the symposium. To be considered as a poster presenter, an abstract must be submitted. All submissions are electronic through the “Abstract Submission” form at the bottom of this page. We welcome clinicians, engineers and researchers to submit an abstract of their work and to display an expanded poster version for viewing and presentation at the IAMPOV symposium.

Abstract submission deadline is 1 April 2020

1. Submission and acceptance criteria:

  • Abstracts must be written in English and submitted via the forms below. The abstract can be included as the body an email, or can be an attachment of one of the following formats: txt, doc, docx, or pdf. If you have any questions about the format of submission, please ask via the contact page.
  • The abstract must address a subject relevant to the symposium.
  • Abstracts will be scored on the following criteria: 1) scientific merit, 2) originality of work, 3) adequate sample size and 4) proper statistical analysis. Submissions with a marketing or commercial focus are discouraged. Reports containing clinical data must be in compliance with Good Clinical Practices, (EN 540), and with the U.S. Food and Drug Administration (FDA) Code of Federal Regulations (CFR): Section 21, Parts 812.2 (b), 812.3 (m), 821.43(d) and 812.46.
  • Submission of an abstract constitutes a commitment by the author(s) to present the abstract as accepted.
  • Posters for accepted abstracts will be continuously displayed during the symposium. Suggestions for displaying your material in a poster format will be included in the correspondence to the primary author of an accepted abstract. All notifications and additional correspondence will be submitted to the contact author indicated within the abstract submission.
  • The abstract and/or information being submitted cannot be previously presented or published. You may submit new research on a topic that was previously presented or published.
  • The abstract should be organized as follows: (a) a sentence describing the purpose of the study; (b) a statement of experimental design or methods used; (c) a summary of results, presented in sufficient detail to support the conclusion; and (d) a statement of conclusion(s) reached. Case reports will not follow this format but should describe the practice, evidence, risk and opportunities associated with symposium-relevant technology. It is not satisfactory to state “The results will be discussed…” or “Other data will be presented.” Use of subtitles to divide sections of an abstract are encouraged, e.g., methods, results, etc. Failure to follow this format will result in a low priority score and may cause rejection of an abstract.
  • The body of an abstract is limited to 4,000 characters (including spaces). The top of the abstract should contain the title, author(s), and institution(s), all of which is limited to 250 characters (including spaces). Do not be concerned with font size or style and page formatting, as these will be managed by the publication group. Tables, graphics, in text citations, and references may be included but at the expense of the previously stated character limitation. No institution or corporate/product logos are allowed. For examples of acceptable formats, review the abstracts from ISIAMOV 2007.
  • Accepted abstracts will be available at the symposium as well as on the symposium web site at www.iampov.org.
  • Please note that the presenter of a poster must complete normal registration formalities, i.e., the cost of registration is not waived. Additionally, expenses associated with the preparation, submission and presentation of an abstract are the responsibility of the presenter(s)/author(s). A board to mount the poster and pins to secure a poster will be provided.

2. Deadline for submission and timing milestones thereafter

  • Abstracts must be submitted by 1 April, 2020
  • Acknowledgement of the receipt of an abstract will be sent to the e-mail address of the person identified as the correspondent on the abstract submission e-mail.
  • The notification of selection status of abstracts (i.e., accepted, accepted pending correction, or reject) will take place after the deadline, and candidates will be informed by e-mail.
  • You are encouraged to submit before the submission deadline.

3. Resubmission/Correction

  • If a correction or alteration to an abstract is desired prior to the 1 APRIL 2020 deadline, the abstract can be resubmitted. Refer to the e-mail received as confirmation of submission of the original abstract and click on the link provided.
  • Abstracts can be resubmitted up until the resubmission deadline stated in the reviewer correspondence.

4. Submit your abstract in the form below